Cardiometabolic risk factors in children with celiac disease on a gluten-free diet

Caterina Anania, Lucia Pacifico, Francesca Olivero, Francesco Massimo Perla, Claudio Chiesa

Caterina Anania, Lucia Pacifico, Francesca Olivero, Francesco Massimo Perla, Policlinico Umberto I Hospital, Sapienza University of Rome, 00161 Rome, Italy

Claudio Chiesa, Institute of Translational Pharmacology, National Research Council, 00133 Rome, Italy

Author contributions: Anania C, Pacifico L and Chiesa C designed the study, analyzed the data and wrote the manuscript; Olivero F and Perla FM collected the data; all the authors participated in the critical review and in the final approval of the manuscript.

Conflict-of-interest statement: There are no potential conflicts of interest relevant to this article.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Claudio Chiesa, MD, Institute of Translational Pharmacology, National Research Council, Via Fosso del Cavaliere 100, 00133 Rome, Italy. claudio.chiesa@ift.cnr.it
Telephone: +39-06-49979215
Fax: +39-06-49979216

Received: February 26, 2017
Peer-review started: February 28, 2017
First decision: May 5, 2017
Revised: May 8, 2017
Accepted: June 6, 2017
Article in press: June 7, 2017
Published online: August 8, 2017

Abstract

Celiac disease (CD) is an immune-mediated systemic condition evoked by gluten and related prolamin in genetically predisposed subjects. It is characterised by a variable combination of gluten-dependent clinical symptoms, CD-specific antibodies, HLA-DQ2 and HLA-DQ8 haplotypes, and enteropathy. The only therapy of CD consists of a life-long gluten free diet (GFD). Strict GFD adherence results in full clinical, serological and histological remission, avoiding long-term complications in CD patients. However, this diet is not without problems. Gluten free products have high levels of lipids, sugar and salt to improve food palatability and consistency, and subjects with CD show an excessive consumption of hypercaloric and hyperlipidic foods to compensate dietetic restriction. GFD may therefore have a negative impact on cardiometabolic risk factors such as obesity, serum lipid levels, insulin resistance, metabolic syndrome, and atherosclerosis. In adults, some studies have suggested that GFD have a beneficial effect on cardiovascular profile, whereas others have shown an atherogenic effect of GFD. In children, very few studies are available on the issue. Thus, the aim of the present narrative review was to analyze the current clinical evidence on the impact of GFD on cardiometabolic risk factors in children with CD.

Key words: Celiac disease; Children; Gluten free diet; Cardiometabolic risk; Atherosclerosis

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Recent epidemiological studies suggest that gluten free diet (GFD) may have adverse effects on body weight, serum lipid levels and insulin resistance in youths with celiac disease (CD). Screening for cardiometabolic risk factors in celiac children is to be recommended not only at diagnosis but also during follow-up since an early intervention may prevent cardiovascular morbidity. Dietary guidance over time, targeting obesity and other components of metabolic syndrome besides monitoring adherence to GFD may be warranted in CD youths.

Anania C, Pacifico L, Olivero F, Perla FM, Chiesa C. Cardiometabolic risk factors in children with celiac disease on a gluten-free diet.
Celiac disease (CD) is an autoimmune systemic condition elicited by ingestion of gluten containing gluten and related prolamines in genetically predisposed subjects. It is characterized by heterogeneous clinical symptoms and signs, specific antibodies including anti-transglutaminase antibodies (tTGA), HLA-DQ2 and HLA-DQ8 haplotypes, and enteropathy. Genetic, immunological and environmental factors therefore appear to be responsible for the disease. In 90% to 95% of patients with CD is present HLA-DQ2, whereas 5% carry the HLA-DQ8 haplotype, and the remaining 5% at least one of the two DQ2 alleles[3,4]. CD affects up to 1% of the population in the western world, and has been related to several complications[3,4]. Nowadays the only accepted treatment is gluten free diet (GFD). It consists in life-long elimination from the diet of gliadin and gluten proteins, fractions contained in wheat, rye, and barley and hybrids like kamut and triticale. Strict GFD adherence leads to full clinical, serological and histological remission and avoids long-term complications in CD patients[9,13,15]. However, this diet is not without problems. Some available reports show that GFD may result in macro- and micronutrient deficiencies; in particular, the dietary intake of patients on GFD is characterized by low levels of fiber, vitamin B, folate, vitamin D, calcium, iron, zinc and magnesium[8-10]. GFD may also have other important consequences. Overweight and obesity have been added to the list of possible nutritional consequences while on GFD, being partially related to hypercaloric content of commercially available gluten-free foods. Indeed, there is clinical evidence indicating an increased caloric intake as well as higher consumption of fats, saturated fats, simplex carbohydrates and food with elevated glycemic index[8-10] with such diets. Gluten free products have high levels of lipids, sugar and salt to improve food palatability and consistency, and subjects with CD show an excessive consumption of hypercaloric and hyperlipidic foods to compensate dietetic restriction. GFD may therefore have a negative impact on cardiometabolic risk factors such as obesity, serum lipid concentrations, insulin resistance, metabolic syndrome, and atherosclerosis.

Whether GFD affects the cardiovascular risk profile in patients with CD remains under discussion. In adults, some studies have suggested that GFD have a beneficial effect on cardiovascular profile consequently to its anti-atherosclerotic effects[11,12], whereas others have shown atherogenic effects of GFD[13,14]. In children, very few studies are available on this topic. Thus, the purpose of the present narrative review was to analyze the current clinical evidence on the impact of GFD on cardiometabolic risk factors in children with CD.

OBESITY

Obesity nowadays is more frequent in CD than in the past. Numerous reports in adults and youths with CD have shown that overweight and obesity is not unusual at diagnosis. The proportion of CD children affected by overweight and obesity at diagnosis is between 8.8% and 20.8% and between 0% and 6%, respectively[13,15,16]. Also, there is some evidence that GFD may predispose to development of overweight and obesity[15-18] for several reasons. First, GFD improves intestinal absorption; second, GFD is an unbalanced diet rich in lipids and proteins[9]; third, CD patients prefer food with elevated caloric fat and protein contents to contrast the GFD unpalatability. The development of increased weight in CD patients may be also linked to the global trend toward overweight and obesity in the pediatric age[19].

There are multiple reports on the association of GFD and obesity in youths with CD, with conflicting results[9,13,15,18,20-27]. Mariani et al[9] first reported a higher rate of overweight and obesity in CD adolescents on GFD in comparison with CD subjects on gluten-containing diet and healthy controls (72% vs 51% and 47%). Valletta et al[13] found that the prevalences of overweight and obesity were 11% and 3%, respectively, at diagnosis in 149 youths with CD. After at least 12 mo of GFD, there was a significant increase in the body mass index (BMI) z-score, and the percentage of overweight children almost doubled (11% vs 21%, P = 0.03). The proportion of obese patients remained the same (3% vs 4%). In a recent cross-sectional multicenter study, Norsa et al[13] evaluated 114 CD children with negative CD serology after at least 1 year of GFD. They found that 9.6% of youths were underweight, 76.3% had normal weight, and 8.8% were overweight, whereas 5.3% were obese. Both prevalences of overweight and obesity rose up to 11.4% and 8%, respectively, after GFD introduction.

Opposite results were reported by Venkatasubramani et al[26], Brambilla et al[16], Reilly et al[18] and Nenna et al[27]. In a retrospective study including 143 CD subjects diagnosed between 1986 and 2003, Venkatasubramani et al[26] identified 7 (5%) patients with a BMI > 95th percentile. After 1-year GFD, BMI increased in 2 (25%), but decreased in 4 (50%). They, therefore, concluded that GFD in obese CD children may reduce BMI. Brambilla et al[16] compared 150 CD children on GFD (median time, 4.4 years) with 288 age- and sex-matched healthy subjects. They evaluated retrospectively BMI changes since CD diagnosis to the latest clinical assessment, and found that the frequencies of overweight and obesity in CD children at diagnosis and during GFD were significantly lower than those reported in healthy controls. The study by Reilly et al[18] involving 142 pediatric CD patients showed that 19% of subjects at diagnosis presented an elevated BMI (12.6% were overweight and 6% were obese), while 74.5% had a normal BMI. Seventy-five percent of children with high BMI at diagnosis had a significant decrease.
in their BMI z-scores on a strict GFD. In particular, 44% of them normalized their BMI z scores. The authors concluded that GFD may have a favorable effect upon the BMI of overweight and obese youths with CD. Finally, in a retrospective study evaluating the prevalence of CD in a large cohort of overweight/obese children and adolescents, Nenna et al(27) observed that the prevalence of CD (1.11%) was similar to that found in general population. Moreover, they demonstrated that these subjects may benefit from a balanced GFD diet.

**SERUM LIPIDS**

The consequences of GFD on lipid profile in childhood have been analyzed in several studies. Rosenthal et al(28) compared plasma lipids and lipoprotein pattern between 12 untreated CD children and 10 control subjects. They found an altered lipid profile characterized by decreased serum triglycerides levels, very low density lipoprotein (VLDL) and apolipoprotein-A-I (apo-A-I), and increased low density lipoprotein cholesterol (LDL-C) in CD children, because of fat malabsorption. On GFD the lipid profile reverted to normal as consequence of improvement of mucosal damage caused by gluten withdraw. Ciampolini et al(29) investigated the plasma lipid levels in CD children (45 under and 49 over 3 years of age, at diagnosis) on GFD, and in comparison with children affected by irritable bowel syndrome (IBS) matched for body size, gender, and age. They found that untreated CD children had significantly lower total and high density lipoprotein cholesterol (HDL-C) levels and significantly higher triglyceride concentrations than IBS controls in both age groups. A period of GFD increased HDL-C in both age groups, while total cholesterol, LDL-C, and triglyceride levels decreased only in the younger age group. Pillan et al(30) compared serum lipids and lipoprotein (a) concentration in 17 adult and pediatric CD patients at diagnosis and after 3 mo of GFD. They found that mean total cholesterol and LDL-C did not significantly change, while mean HDL-C significantly rose and mean triglyceride levels significantly decreased after the diet, suggesting that GFD may positively influence lipid profile. Recently, in a cross-sectional prospective study, Forchielli et al(31) analyzed the impact of GFD on serum lipid concentrations in children with CD compared with the general pediatric population. They studied 235 CD children and adolescents: In 205 patients the lipid profile was available only after diagnosis (group 1), whereas in 30 patients it was available both before and after GFD (group 2). The Authors found that in group 1, total cholesterol, triglyceride, and HDL-C concentrations were significantly elevated in girls in comparison with boys. Furthermore, compared with the general pediatric population, group 1 girls had higher total cholesterol, triglycerides, HDL-C and LDL-C, while group 1 boys had lower total cholesterol, triglycerides and LDL-C, and higher HDL-C. In group 2, total cholesterol did not change over time, triglycerides diminished, and HDL-C increased. They therefore suggested that GFD, being appropriate in terms of fibers and unsaturated fats(32), may have a positive influence on lipid profiles, determining higher HDL-C in CD children than in the reference population.

Against this background, Médiène et al(32), who compared 46 CD adult and pediatric patients and 155 control subjects, found that untreated CD patients had decreased cholesterol, phospholipid and apo-A-I levels and elevated triglycerides. However, they did not find a return towards normal lipid profile following GFD.

**INSULIN RESISTANCE**

There are only few studies on insulin resistance in both CD adults and youths on GFD. In a retrospective study evaluating the effects of 1-5 years of GFD on markers of cardiovascular risk in a large cohort of adult patients, Zanini et al(32) found that insulin resistance remained constant from baseline to follow-up. Of note, absolute levels of serum glucose rose from 87.9 mg/dL at baseline to 89.7 mg/dL during GFD (P = 0.0001), reaching statistically significance only in females. In a sample of Italian and Israeli CD patients on GFD, Norsa et al(33) found that 3.5% of 114 children on GFD had insulin resistance. Because of lack of data on insulin values before CD diagnosis, the authors were not able to determine whether insulin resistance could be, indeed, attributed to the start of GFD.

**METABOLIC SYNDROME**

Data regarding the prevalence of metabolic syndrome (MetS) in patients with CD on free diet or on GFD are still scarce and limited to adults with CD. In an observational prospective study involving 98 adult CD patients, Tortora et al(33) found that 2% of them fulfilled the diagnostic criteria for MetS at diagnosis while 29.5% after one year of GFD. Among the MetS components, there was a significant increase in BMI, waist circumference, blood pressure and blood glucose levels, whereas no significant difference was detected in the lipid profile from baseline to 12 mo after the introduction of GFD. They concluded that patients with CD on GFD are at risk of developing MetS. In contrast, Kabbani et al(34) comparing 26 CD adults with 81 controls, reported that MetS is less frequent in CD than in controls (3.5% vs 12.7%, P < 0.0001).

Nonalcoholic fatty liver disease (NAFLD), considered as the hepatic component of MetS, is the most frequent cause of chronic liver disease in youths worldwide. Potential triggers for NAFLD including metabolic risk factors (i.e., abdominal adiposity and insulin resistance) as well as altered intestinal permeability may be present in CD patients. However, there are very few reports of NAFLD in subjects with CD. Recently, Reilly et al(35) compared the risk of NAFLD diagnosed between 1997 and 2009 in 26816 pediatric and adult CD patients with that in 130051 age-, gender-, calendar year-, and...
countingmatched subjects. They observed a 4.2-fold increased risk of NAFLD in the first five years after diagnosis of CD. This increased risk was mainly due to NAFLD diagnosed in the first year after diagnosis of CD, but was still significantly high 15 years after the diagnosis of CD.

**SUBCLINICAL ATHEROSCLEROSIS**

Several studies have shown that atherosclerosis begins in childhood and progresses into adulthood. Early detection of arterial damage is fundamental to prevent future vascular risk since subclinical atherosclerosis can be reversible if detected earlier and intervention is provided. Subjects at high risk for cardiovascular disease (CVD) may be identified by determination of arterial thickness and distensibility, endothelial function, proinflammatory and prothrombotic state alone or in combination. Altered flow-mediated vasodilatation, as well as increased carotid-artery intimal medial thickness (cIMT) can be assessed by ultrasonography allowing an early diagnosis of preclinical atherosclerosis. Arterial stiffness can be assessed by pulse wave velocity (PWV) measurement, the main index for estimating arterial elasticity.

Endothelial dysfunction and increased arterial stiffness have been reported in adult patients with CD. To the best of our knowledge, only Demir et al. investigated markers of preclinical atherosclerosis in children with CD. In a cross-sectional study, the authors studied arterial stiffness and thickness using PWV and cIMT in 37 pediatric patients with CD compared to 36 age- and sex-matched healthy controls. A strict adherence to GFD, evaluated by determination of tTGA levels, was detected in 59.4% of 37 CD patients. There was no significant difference between tTGA positive and tTGA negative children in terms of PWV and cIMT. Nonetheless, cIMT was significantly lower in CD subjects adherent to GFD in comparison with healthy controls. Moreover, cIMT was positively associated with tTGA levels in patients with CD, suggesting that lack of dietary compliance in such patients might pave the road to arterial thickness. These results suggest that GFD is likely to be anti-atherogenic, and that long-term gluten withdrawal might prevent premature atherosclerosis.

**CV RISK PROFILE**

Several studies have reported an increased risk of CVD as well as an increased risk of death for CVD in CD patients, especially those with untreated CD, in comparison with the general population. In a systematic review and meta-analysis, Emilsson et al. reported that CD was associated with a 10% increased risk of CVD, but some studies did not confirm these data. Of note, it has been suggested that transglutaminases can modulate several cardiovascular risk factors, mainly hypertension, atherosclerosis, vascular permeability and angiogenesis.

To our knowledge, only two studies have explored the cardiovascular risk profile in children with CD. In a cross-sectional multicenter study involving 114 CD children on GFD, Norsa et al. reported the profile of CVD risk factors including obesity, abdominal obesity, high LDL-C, high triglycerides, hypertension, and insulin resistance. The main prevalent CVD risk factors were elevated triglycerides (34.8%), hypertension (29.4%), and elevated serum levels of LDL-C (24.1%). The Authors found 3 or more coexistent risk factors for CVD in 14% of the entire cohort, whereas absence of risk factors was found in only 30.7% of the cohort. Moreover, significant increments in both total cholesterol and HDL-C were found in CD children on GFD. This is in line with some authors arguing that alteration of intestinal absorption, chylomicron production and lipoprotein metabolism may underlie the presence of lower concentrations of total cholesterol and HDL-C in CD subjects at diagnosis, which can return to normal levels after GFD. Therefore, they highlight the critical role of screening for cardiovascular risk factors in CD youths at diagnosis as well as at follow-up. Very recently, in a retrospective study Assa et al. found that at the age of 17 years the prevalence of certain CVD risk factors such as hypercoagulability, hyperlipidemia, and type 2 diabetes was higher in adolescents with CD compared to the general population. In contrast, the prevalence of traditional cardiovascular risk factors such as high blood pressure and overweight/obesity was similar between the two groups. However, these findings should be cautiously interpreted since information on age at diagnosis as well as on GFD adherence was not available.

Early cardiac involvement in youths with CD and the impact of GFD on this issue have also been evaluated. Lionetti et al. compared cardiac structure and function before and after 1 year of GFD in 60 children with CD and in a control group of 45 healthy children. There were significantly lower contractility indices, and higher left ventricular dimensions in untreated CD. Notably, these parameters reverted to normal after GFD. Interestingly, GFD, along with immunosuppression, can be effective in CD-associated autoimmune myocarditis.

**CONCLUSION**

The available literature shows conflicting data on the effects of GFD on cardiometabolic risk factors in children and adolescents with CD. The majority of the studies indicate changes in markers associated with cardiovascular risk. These variations, in any case, do not constantly point at a better or worse cardiovascular risk profile. Limitations of most studies comprise the relatively small sample size, the cross-sectional design that does not permit comparison between pre- and post-GFD values of the evaluated parameters, and the absence of knowledge of familial history for CVD risk factors. Therefore, additional longitudinal, well-
designed studies involving a large number of children with long-term follow-up are necessary to clarify whether prolonged exposure to GFD might result in an increased cardiometabolic risk. At this time, GFD remains the milestone of CD treatment. Nonetheless, an in-depth assessment of nutritional status along with cardiometabolic screening in CD children at diagnosis and during GFD have to be recommended because an early intervention may prevent cardiovascular morbidity. Dietary guidance over time, targeting obesity and other components of MetS besides monitoring adherence to GFD may be warranted in youths with CD.

REFERENCES

1. Fasano A, Catassi C. Clinical practice. Celiac disease. N Engl J Med 2012; 367: 2419-2426 [PMID: 23252527 DOI: 10.1056/NEJMr0903833]

2. Husby S, Kolektzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgemann M, Mäki M, Mäki R, Ribes-Koninckx C, Ventura A, Zimmer KP. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54: 136-160 [PMID: 22197856 DOI: 10.1097/MPG.0b013e31821a2d80]

3. Mäki M, Mustalathi K, Kulkoven J, Kulmala P, Haapalahti M, Viti MG, Montuori M, La Vecchia A, Cipolletta E, Calvani M, Mandato C, Vauro P. Atypical celiac disease presenting as obesity-obese children: clinical features and growth outcomes following a gluten-free diet. Pediatr Gastroenterol Nutr 2011; 53: 528-531 [PMID: 21670710 DOI: 10.1097/MPG.0b013e318227fde5]

4. Thompson T, Dennis M, Higgins LA, Lee AR, Sharrett MK. Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? J Hum Nutr Diet 2005; 18: 163-169 [DOI: 10.1111/j.1365-277X.2005.00675.x]

5. Thompson T, Folate, iron, and dietary fiber contents of the gluten-free diet. Am J Dis Child 2000; 100: 1389-1396 [PMID: 11103663 DOI: 10.1061/S0002-8223(00)00386-2]

6. Thompson T, Dennis M, Higgins LA, Lee AR, Sharrett MK. Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? J Hum Nutr Diet 2005; 18: 163-169 [DOI: 10.1111/j.1365-277X.2005.00675.x]

7. Barton SH, Kelly DG, Murray JA. Nutritional deficiencies in celiac disease. Gastroenterol Clin North Am 2007; 36: 93-108 [PMID: 17472877 DOI: 10.1016/j.gcc.2007.01.006]

8. Koppelin T, Uusitupa M, Janatuinen E, Järvinen R, Julkunen R, Uusitupa M, Vania A. Coeliac disease screening among a large cohort of children: clinical features and growth outcomes following a gluten-free diet. Pediatr Gastroenterol Nutr 2001; 33: 329-332 [PMID: 11593131]

9. Oso O, Fraser NC. A boy with coeliac disease and obesity. Acta Paediatr 2006; 95: 618-619 [PMID: 16825144 DOI: 10.1111/j.1651-2227.2006.00292.x]

10. Aarsland N, Eson I, Dencker C, Vilsma J, Unuvar T, Bober E. The changing face of celiac disease: a girl with obesity and celiac disease. J Pediatr Child Health 2009; 45: 317-318 [PMID: 19493125 DOI: 10.1111/j.1440-1754.2009.01512.x]

11. Venkataraman N, Telega G, Welrin SL. Obesity in pediatric celiac disease. J Pediatr Gastroenterol Nutr 2010; 51: 295-297 [PMID: 20479683 DOI: 10.1097/MPG.0b013e3181e365a]

12. Nenna R, Mosca A, Mennini M, Papa RE, Petrarca L, Mercurio R, Montuori M, Piedimonte A, Bavastrelli M, De Luca IC, Bonamico M, Vania A. Coeliac disease screening among a large cohort of overweight/obese children. J Pediatr Gastroenterol Nutr 2015; 60: 405-407 [PMID: 25714583 DOI: 10.1097/MPG.0000000000000656]

13. Rosenthal E, Hoffman R, Aviram A, Vardy E, Brook JG. Serum lipoprotein profile in children with celiac disease. J Pediatr Gastroenterol Nutr 1990; 11: 58-62 [PMID: 2388134]

14. Ciampolli M, Bini S. Serum lipids in celiac children. J Pediatr Gastroenterol Nutr 1991; 12: 459-460 [PMID: 1865279]

15. Pillar MN, Spaduari S, Simeoni I, Meni A, Scalaioni T, Balestrieri GP. Effects of a gluten-free diet on serum lipids and lipoprotein (a) levels in a group of patients with celiac disease. J Pediatr Gastroenterol Nutr 1994; 18: 183-185 [PMID: 8017465]

16. Forcelli ML, Fernicola P, Diani L, Scriver B, Salit NC, Pessina AC, Lima M, Conti V, Pession A. Gluten-Free Diet and Lipid Profile in Children With Celiac Disease: Comparison With General Population Standards. J Pediatr Gastroenterol Nutr 2015; 61: 224-229 [PMID: 26368807 DOI: 10.1016/j.jpdd.2013.04.001]
Anania C et al. Cardiometabolic risk and pediatric celiac disease

25782659 DOI: 10.1097/MGP.0000000000000785

32 Miedrich S, Hakem S, Bard JM, Medjajou I, Benhammouch S, Lebel P, Fruchart JC, Clavéy V. Serum lipoprotein profile in Algerian patients with celiac disease. Clin Chim Acta 1995; 235: 189-196 [PMID: 7554273 DOI: 10.1016/0009-8981(95)80824-1]

33 Tortora R, Capone P, De Stefano G, Imperatore N, Gerbino N, Donetto S, Monaco V, Caporaso N, Rispo A. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther 2015; 41: 352-359 [PMID: 25581084 DOI: 10.1111/apt.13062]

34 Kabbani TA, Kelly CP, Betensky RA, Hansen J, Pallav K, Villafuerte-Gámez VA, Varga R, Mukherjee H, Norton A, Dennis M, Leffler DA. Patients with celiac disease have a lower prevalence of non-insulin-dependent diabetes mellitus and metabolic syndrome. Gastroenterology 2013; 144: 912-917.e1 [PMID: 23354016 DOI: 10.1053/j.gastro.2013.01.033]

35 Reilly NR, Lebwolh B, Hultcrantz R, Green PH, Ludvigsson JF. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. J Hepatol 2015; 62: 1405-1411 [PMID: 25617505 DOI: 10.1016/j.jhep.2015.01.013]

36 Stary HC. Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. Am J Clin Nutr 2000; 72: S1297-S1306 [PMID: 11063472]

37 Pacifico L, Nobili V, Anania C, Verdeccchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011; 17: 3082-3091 [PMID: 21912450 DOI: 10.3748/wjg.v17.i26.3082]

38 Simons PC, Algra A, Bols ML, Grobbée DE, van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of Atherosclerotic Risk Trial). Circulation 1999; 100: 951-957 [PMID: 10468526 DOI: 10.1161/01.CIR.100.9.951]

39 Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Liebermann EH, Ganz P, Creager MA, Yeung AC. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241 [PMID: 7594037 DOI: 10.1016/0735-1097(95)00327-4]

40 Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Assar R, Reneman RS, Hoeks AP, Breiteler MM, Wittenman JC. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657-663 [PMID: 16461838 DOI: 10.1161/CIRCULATIONAHA.105.555235]

41 Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelium-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265 [PMID: 11788217]

42 Zhang Y, Agnoletti D, Protogerou AD, Topouchian J, Wang JG, Xu Y, Blacher J, Safar ME. Characteristics of pulse wave velocity in elastic and muscular arteries: a mismatch beyond age. J Hypertens 2013; 31: 554-559; discussion 559 [PMID: 23615212 DOI: 10.1097/JHJ.0b013e32835d4ace]

43 Sari C, Bayram NA, Doğan FE, Baştıg Ş, Bolat AD, Sari SÖ, Ersoy O, Bozkurt E. The evaluation of endothelial functions in patients with celiac disease. Echocardiography 2012; 29: 471-477 [PMID: 22150763 DOI: 10.1111/j.1540-8175.2011.0598.x]

44 Korkmaz H, Sozen M, Kebapciar L. Increased arterial stiffness and its relationship with inflammation, insulin, and insulin resistance in celiac disease. Eur J Gastroenterol Hepatol 2015; 27: 1193-1199 [PMID: 26181110 DOI: 10.1097/MEG.0000000000000437]

45 Demir AM, Kuloğlu Z, Yaman A, Fütüz S, Nergizöğlu G, Kansu A. Carotid intima-media thickness and arterial stiffness as early markers of atherosclerosis in pediatric celiac disease. Turk J Pediatr 2016; 58: 172-179 [PMID: 27976558]

46 Ludvigsson JF, James S, Asking J, Stenestrand U, Ingelsön E. Nationwide cohort study of risk of ischemic heart disease in patients with celiac disease. Circulation 2011; 123: 483-490 [PMID: 21262996 DOI: 10.1161/CIRCULATIONAHA.110.965624]

47 Emilsson L, Carlsson R, James S, Hambraeus K, Ludvigsson JF. Follow-up of ischaemic heart disease in patients with coeliac disease. Eur J Prev Cardiol 2015; 22: 83-90 [PMID: 23963400 DOI: 10.1177/204748331502446]

48 Emilsson L, Lebwolh B, Sandström J, Ludvigsson JF. Cardiovascular disease in patients with coeliac disease: A systematic review and meta-analysis. Dig Liver Dis 2015; 47: 847-852 [PMID: 26160499 DOI: 10.1016/j.dld.2015.06.004]

49 Grainge MJ, West J, Card TR, Holmes GK. Causes of death in people with celiac disease spanning the pre- and post-serology era: a population-based cohort study from Derby, UK. Am J Gastroenterol 2011; 106: 933-939 [PMID: 21245833 DOI: 10.1038/ajg.2010.506]

50 Abdul Sultan A, Crooks CJ, Card T, Tata LJ, Fleming KM, West J. Causes of death in people with celiac disease in England compared with the general population: a competing risk analysis. Gut 2015; 64: 1220-1226 [PMID: 25344479 DOI: 10.1136/gutjnl-2014-308285]

51 Sane DC, Konts LS, Greenberg CS. Roles of transglutaminases in cardiac and vascular diseases. Front Biosci 2007; 12: 2530-2545 [PMID: 17127261]

52 Lewis NR, Sanders DS, Logan RF, Fleming KM, Hubbard RB, West J. Cholesterol profile in people with newly diagnosed coeliac disease: a comparison with the general population and changes following treatment. Br J Nutr 2009; 102: 509-513 [PMID: 19660152 DOI: 10.1017/S0007114509272428]

53 Assa A, Frenkel-Nir Y, Tzur D, Katz LH, Shamir R. Cardiovascular Risk Factors in Adolescents With Celiac Disease: A Cross Sectional Population Based Study. J Pediatr Gastroenterol Nutr 2017; 65: 190-194 [PMID: 27906796 DOI: 10.1097/MPG.0000000000001487]

54 Lioniotti E, Cattaci S, Francavilla R, Miraglia Del Giudice M, Sciacca P, Arrigo T, Leonardi S, Salpietro A, Salpietro C, La Rosa M. Subclinical cardiac involvement in paediatric patients with celiac disease: a novel sign for a case finding approach. J Biol Regul Homeost Agents 2012; 26: S63-S68 [PMID: 22691252]

55 Frustraci A, Cuoco L, Chimenti C, Pieroni M, Fioravanti G, Gentiloni N, Maseri A, Gabbarini G. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105: 2611-2618 [PMID: 12045166 DOI: 10.1161/01.CIR.0000017880.86166.87]

P- Reviewer: Huan C S- Editor: Qi Y L- Editor: A E- Editor: Lu YJ

WJCP | www.wjgnet.com 148 August 8, 2017 | Volume 6 | Issue 3 |
